ARSENIC Toxicity
Arsenic is released into the air by volcanoes and is a natural contaminant of some deep-water wells.
Occupational exposure to arsenic is common:
- In the smelting industry in which arsenic is a byproduct of ores containing lead, gold, zinc, cobalt, and nickel
- In the microelectronics industry, in which gallium arsenide is responsible.
- Commercial use of inorganic arsenic compounds in common products such as wood preservatives, pesticides, herbicides, fungicides, and paints.
- Through the consumption of foods and the smoking of tobacco treated with arsenic-containing pesticides
- Through the burning of fossil fuels in which arsenic is a contaminant.
- Arsenic was also a major ingredient of Fowler’s solution and continues to be found in some folk remedies.
Fowler’s solution is a solution containing potassium arsenite that once was prescribed as a remedy or a tonic. A Dr. Fowler of Stafford, England proposed its use in 1786 as a substitute for a patented medicine, It was prescribed in the United States until the late 1950s for a range of ailments including malaria, chorea, and syphilis. In 2001 the U.S. FDA approved a proprietary formula of a solution of arsenic trioxide for acute promyelocytic leukaemia.Fowler’s solution, is a 1% solution of potassium arsenite, KH2AsO3.Because of the poisonous and carcinogenic nature of arsenic compounds, Fowler’s solution is dangerous. Documented side effects of treatment with Fowler’s solution include: cirrhosis of the liver, idiopathic portal hypertension, urinary bladder cancer, skin cancers. |
Metabolism
The toxicity of an arsenic-containing compound depends on its valence state (zero-valent, trivalent, or pentavalent), its form (inorganic or organic), and the physical aspects governing its absorption and elimination. In general, inorganic arsenic is more toxic than organic arsenic, and trivalent arsenite is more toxic than pentavalent and zero-valent arsenic.The normal intake of arsenic by adults occurs primarily through ingestion and averages around 50 ug/d (range, 8 to 104 ug/d). Most (around 64 percent) of this amount is accounted for by organic arsenic from fish, seafood, and algae; the specific arsenic compounds obtained from these sources are arsenobentaine and arsenocholine, which are relatively nontoxic and are rapidly excreted in unchanged form in the urine. After absorption, inorganic arsenic accumulates in the liver, spleen, kidneys, lungs, and gastrointestinal tract. It is then rapidly cleared from these sites but leaves a residue in keratin-rich tissues such as skin, hair, and nails. Arsenite (+5) undergoes biomethylation in the liver to the less toxic metabolites methylarsenic acid and dimethylarsenic acid; biomethylation can quickly become saturated, however, and the result is the deposition of increasing doses of inorganic arsenic in soft tissues. Arsenic, particularly in its trivalent form, inhibits critical sulfhydryl-containing enzymes. In the pentavalent form, the competitive substitution of arsenic for phosphate can lead to rapid hydrolysis of the high-energy bonds in compounds such as ATP. |
CLINICAL FEATURESAcute arsenic poisoning from ingestion results in increased permeability of small blood vessels and![]() ![]() |
LABORATORY FINDINGSWhen acute arsenic poisoning is suspected, an x-ray of the abdomen may reveal ingested arsenic, which is radiopaque. The serum arsenic level may exceed 0.9 umol/L (7 ug/dL); however, arsenic is rapidly cleared from the blood.Electrocardiographic findings may include QRS complex broadening, QT prolongation, ST-segment depression, T-wave flattening, and multifocal ventricular tachycardia. Urinary arsenic should be measured in 24-h specimens collected after 48 h of abstinence from seafood ingestion; normally, levels of total urinary arsenic excretion are less than 0.67 umol/d (50 ug/d).Arsenic may be detected in the hair and nails for months after exposure.Abnormal liver function, anemia, leukocytosis or leukopenia, proteinuria, and hematuria may be detected.Electromyography may reveal features similar to those of Guillain-Barre syndrome. |
TREATMENT
|
—